On March 21, Harvest SSE Science and Technology Innovation Board Biomedical ETF (588700) closed down 2.02%, with a turnover of 22.1872 million yuan.
Sci-Tech Pharmaceutical Index ETF (588700) was established on December 27, 2023, and the full name of the fund is Harvest SSE Science and Technology Innovation Board Biomedical Exchange-traded Open-ended Index Securities Investment Fund, and the fund is referred to as Harvest SSE Science and Technology Innovation Board Biomedical ETF. The fund has a management fee of 0.50% per annum and a custody fee of 0.10% per annum. The performance benchmark of the Science and Technology Innovation Pharmaceutical Index ETF (588700) is the return rate of the SSE Science and Technology Innovation Board Biomedical Index.
In terms of scale, as of March 20, the latest share of the Science and Technology Innovation Pharmaceutical Index ETF (588700) was 400 million shares, and the latest scale was 377 million yuan. Looking back on December 31, 2024, the share of the Science and Technology Innovation Pharmaceutical Index ETF (588700) was 365 million, with a scale of 303 million yuan. That is, the share of the fund has increased by 9.58% and the scale has increased by 24.17% since the beginning of this year.
In terms of liquidity, as of March 21, the cumulative turnover of the Science and Technology Innovation Pharmaceutical Index ETF (588700) in the past 20 trading days was 605 million yuan, with an average daily turnover of 30.2429 million yuan, and since the beginning of this year, the cumulative turnover in 51 trading days has been 1.312 billion yuan, with an average daily turnover of 25.7182 million yuan.
The current fund manager of the Science and Technology Innovation Pharmaceutical Index ETF (588700) is Wang Zihan. Wang Zihan has managed (or intends to manage) the fund since December 27, 2023, with a return of -5.95% during his tenure.
According to the latest regular report, the heavy stocks of the Science and Technology Innovation Pharmaceutical Index ETF (588700) include United Imaging Medical, Huitai Medical, BeiGene, Baili Tianheng, Junshi Biosciences, Allist, Aibo Medical, Tebao Biotech, Zelgen Pharmaceutical, and Bloomage Biotech, with the following proportions.
| stock symbol | ,stock name | ,position ratio | , number of shares held (shares). | Market value of the position (RMB). |
| 688271 | United Imaging Medical | 9.64%, | 231,429,246,100 | |
| 688617 | Huitai Medical | 6.35%, | 51,719,249,500 | |
| 688235 | BeiGene: | 5.41%, | 101,800, | 16,394,300 |
| 688506 | Baili Tianheng | 4.48%, | 70,913,596,100||
| 688180 | Junshi Biosciences | 4.28%, | 475,200, | 12,986,600 |
| 688578 | Allist | , 3.94%, | 199,311,938,500 | |
| 688050 | Aibo Medical | 3.53% | 117,5010,696,500||
| 688278 | Tebao Biotech | 3.49% | 144,10574,600 | |
| 688266 | Zejing Pharmaceutical: | 3.37%, | 164,000 | , 10,217,800 |
| 688363 | Bloomage Biotech, | 2.87%, | 170,787,711,000 |
Risk Warning: The market is risky, and investment needs to be cautious. This article is automatically released by the AI model, and any information appearing in this article (including but not limited to individual stocks, comments, forecasts, charts, indicators, theories, any form of expression, etc.) is for reference only and does not constitute personal investment advice. The MACD golden cross signal is formed, and these stocks are rising well!
Ticker Name
Percentage Change
Inclusion Date
